Clinical Trials · NCT03061214
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 868
- Start date
- Aug 2017
- Locations
- 67 sites, 7 countries
- Primary endpoint
- Change in HbA1c